Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LYRA Stock Forecast 2025-2026
$0.11
Current Price
$6.92M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to LYRA Price Targets
+1,804.8%
To High Target of $2.00
+1,090.5%
To Median Target of $1.25
+376.2%
To Low Target of $0.50
LYRA Price Momentum
+11.1%
1 Week Change
-28.6%
1 Month Change
-97.9%
1 Year Change
-52.4%
Year-to-Date Change
-98.1%
From 52W High of $5.65
+28.0%
From 52W Low of $0.08
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Lyra Therapeutics (LYRA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LYRA and similar high-potential opportunities.
Latest LYRA Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, LYRA has a neutral consensus with a median price target of $1.25 (ranging from $0.50 to $2.00). Currently trading at $0.11, the median forecast implies a 1,090.5% upside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 1,804.8% upside. Conversely, the most conservative target is provided by Dennis Ding at Jefferies, suggesting a 376.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LYRA Analyst Ratings
0
Buy
4
Hold
0
Sell
LYRA Price Target Range
Low
$0.50
Average
$1.25
High
$2.00
Current: $0.11
Latest LYRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LYRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Aug 15, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| May 7, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| May 7, 2024 | Jefferies | Dennis Ding | Hold | Downgrade | $0.50 |
| May 6, 2024 | BTIG | Justin Zelin | Neutral | Downgrade | $0.00 |
| May 1, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 25, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $11.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Oct 6, 2023 | BTIG | Justin Zelin | Buy | Assumes | $15.00 |
| Oct 2, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Sep 12, 2023 | B of A Securities | Jason Gerberry | Buy | Maintains | $15.00 |
| Aug 31, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $12.00 |
| Feb 7, 2023 | BTIG | Robert Hazlett | Buy | Maintains | $20.00 |
| May 24, 2022 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $15.00 |
| May 26, 2020 | B of A Securities | Buy | Initiates | $0.00 | |
| May 26, 2020 | Jefferies | Buy | Initiates | $0.00 |
Lyra Therapeutics Inc. (LYRA) Competitors
The following stocks are similar to Lyra Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LYRA
Lyra Therapeutics
mkt cap
6.53M
Lyra Therapeutics Inc. (LYRA) Financial Data
Lyra Therapeutics Inc. has a market capitalization of $6.92M with a P/E ratio of 0.0x. The company generates $1.53M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +43.2% quarter-over-quarter, while maintaining an operating margin of -4,672.7% and return on equity of -185.0%.
Valuation Metrics
Market Cap
$6.92M
Enterprise Value
$720,458
P/E Ratio
0.0x
PEG Ratio
-0.1x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+43.2%
Gross Margin
N/A
Operating Margin
-4,672.7%
Net Margin
0.0%
EPS Growth
+43.2%
Financial Health
Cash/Price Ratio
+586.7%
Current Ratio
3.4x
Debt/Equity
296.5x
ROE
-185.0%
ROA
-36.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Lyra Therapeutics Inc. (LYRA) Business Model
About Lyra Therapeutics Inc.
What They Do
Develops therapies for ear, nose, and throat diseases.
Business Model
Lyra Therapeutics Inc. generates revenue by developing and commercializing innovative therapies specifically designed for chronic rhinosinusitis and related ENT conditions. By leveraging its proprietary XTreo platform, the company focuses on delivering medications directly to the site of illness, which enhances treatment effectiveness and minimizes side effects.
Additional Information
The company aims to significantly improve patient outcomes in the ENT sector, positioning itself as a leader in the specialty pharmaceuticals market. Its unique approach to localized therapy addresses unmet medical needs, potentially transforming how ENT diseases are managed.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Dr. Maria Palasis Ph.D.
Country
United States
IPO Year
2020
Website
lyratherapeutics.comLyra Therapeutics Inc. (LYRA) Latest News & Analysis
Latest News
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported its Q4 and full-year financial results for 2024, focusing on its development of sinonasal implants for chronic rhinosinusitis.
Why It Matters
Lyra's financial results and corporate update signal its progress in developing innovative treatments, potentially impacting stock performance and market confidence in biotechnology investments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lyra Therapeutics (LYRA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increasing optimism about its earnings prospects.
Why It Matters
Lyra Therapeutics' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
5 months ago
Quick Summary
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported its Q3 2024 financial results and provided a corporate update on its sinonasal implants for chronic rhinosinusitis treatment.
Why It Matters
Lyra Therapeutics' financial results and corporate update may indicate its progress in product development, influencing investor sentiment on future profitability and market potential in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lyra Therapeutics reported a quarterly loss of $0.18 per share, better than the expected loss of $0.23 and an improvement from a loss of $0.27 per share a year earlier.
Why It Matters
Lyra Therapeutics reported a smaller-than-expected quarterly loss, indicating improved financial performance and potential for future growth, which could positively influence investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Lyra Therapeutics has fully enrolled its Phase 3 ENLIGHTEN 2 trial for LYR-210, a treatment for chronic rhinosinusitis. Topline results are anticipated in Q2 2025.
Why It Matters
The full enrollment of the ENLIGHTEN 2 trial and upcoming results in Q2 2025 could significantly impact Lyra Therapeutics' stock price and market perception, reflecting the potential success of LYR-210.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lyra Therapeutics (Nasdaq: LYRA) will present Phase 3 results for LYR-210 and Phase 2 results for LYR-220 at two major medical conferences in Miami from September 27 to October 1, 2024.
Why It Matters
Lyra Therapeutics' presentation of Phase 3 and Phase 2 study results could indicate therapeutic efficacy and regulatory progress, impacting stock performance and investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LYRA Stock
What is Lyra Therapeutics Inc.'s (LYRA) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Lyra Therapeutics Inc. (LYRA) has a median price target of $1.25. The highest price target is $2.00 and the lowest is $0.50.
Is LYRA stock a good investment in 2025?
According to current analyst ratings, LYRA has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LYRA stock?
Wall Street analysts predict LYRA stock could reach $1.25 in the next 12 months. This represents a 1,090.5% increase from the current price of $0.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lyra Therapeutics Inc.'s business model?
Lyra Therapeutics Inc. generates revenue by developing and commercializing innovative therapies specifically designed for chronic rhinosinusitis and related ENT conditions. By leveraging its proprietary XTreo platform, the company focuses on delivering medications directly to the site of illness, which enhances treatment effectiveness and minimizes side effects.
What is the highest forecasted price for LYRA Lyra Therapeutics Inc.?
The highest price target for LYRA is $2.00 from Matthew Caufield at HC Wainwright & Co., which represents a 1,804.8% increase from the current price of $0.11.
What is the lowest forecasted price for LYRA Lyra Therapeutics Inc.?
The lowest price target for LYRA is $0.50 from Dennis Ding at Jefferies, which represents a 376.2% increase from the current price of $0.11.
What is the overall LYRA consensus from analysts for Lyra Therapeutics Inc.?
The overall analyst consensus for LYRA is neutral. Out of 7 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $1.25.
How accurate are LYRA stock price projections?
Stock price projections, including those for Lyra Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:34 PM UTC